SCHEMBL7708189

SCHEMBL7708189

CC1=C(N)Nc2cc(CN(Cc3ccc(C)cc3)C(=O)OC(C)(C)C)ccc2O1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC3 O15379 2/20 0.37
HDAC1 Q13547 2/20 0.37
HDAC2 Q92769 2/20 0.37
NCOR2 Q9Y618 2/20 0.37
ALOX15 P16050 1/20 0.33
HSD17B10 Q99714 1/20 0.33
TRPM8 Q7Z2W7 1/20 0.31
USP2 O75604 2/20 0.31
GAA P10253 1/20 0.31
KDM4E B2RXH2 2/20 0.31
HPGD P15428 2/20 0.31
MEN1 O00255 1/20 0.31
KMT2A Q03164 1/20 0.31
POLB P06746 3/20 0.31
CHEK1 O14757 1/20 0.31
MAPT P10636 2/20 0.31
ALDH1A1 P00352 1/20 0.31
SMN1; SMN2 Q16637 1/20 0.31
TP53 P04637 1/20 0.31
STAT5B P51692 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7711366 0.94 HDAC1 (0.37) HDAC3HDAC1HDAC2NCOR2CHEK1
SCHEMBL7704910 0.93 HDAC1 (0.45) HDAC3HDAC1HDAC2NCOR2ALOX15
SCHEMBL7708353 0.92 GRM2 (0.37) HDAC3HDAC1HDAC2NCOR2TRPM8
SCHEMBL7704965 0.92 HDAC3 (0.36) HDAC3HDAC1HDAC2NCOR2GAA
SCHEMBL7711328 0.91 HDAC3 (0.35) HDAC3HDAC1HDAC2NCOR2MEN1
SCHEMBL7704946 0.91 ALDH1A1 (0.38) HDAC3HDAC1HDAC2NCOR2HSD17B10
SCHEMBL7713435 0.89 HDAC1 (0.34) HDAC3HDAC1HDAC2NCOR2MEN1
SCHEMBL7710748 0.89 CA2 (0.35) HDAC3HDAC1HDAC2NCOR2KDM4E
SCHEMBL7711458 0.89 HDAC3 (0.33) HDAC3HDAC1HDAC2NCOR2HPGD
SCHEMBL7708350 0.89 NR1D1 (0.40) HDAC3HDAC1HDAC2NCOR2POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6365736-B1 TREATMENT OF NERVOUS SYSTEM DISORDERS, CARDIOVASCULAR DISORDERS AND FOR ACTIVITY AS NO-SYNTHASES (NOS) INHIBITORS. SCHERING AKTIENGESELLSCHAFT (DE) 2002-04-02 US disclosed